Skip to main content
. Author manuscript; available in PMC: 2013 Mar 19.
Published in final edited form as: Nat Neurosci. 2011 Dec 25;15(2):197–204. doi: 10.1038/nn.3019

Figure 3. mNSCs expressing therapeutic S-TRAIL induce GBM cell death in vitro.

Figure 3

(a–e) mNSCs (green) expressing Ss-Rluc(o) or S-TRAIL were encapsulated in sECM and placed in a culture dish containing human GBM U87-Fluc-mCherry cells (red). Photomicrographs show sECM-encapsulated mNSCs at 8 h (a,c) and 24 h (b,d). Plot shows tumor cell viability (*P < 0.05 versus controls) and caspase-3/7 activation (*P < 0.05 versus mNSC-S-TRAIL) over 24 h when cultured with either sECM-encapsulated mNSC-GFP or mNSC-S-TRAIL cells (e). (f) Western blot analysis on GBM cells collected 8 h after sECM-encapsulated mNSC-S-TRAIL or mNSC-GFP (control) cell placement in the culture dish (see Supplementary Fig. 4 for uncropped blots). (g) Representative images and summary graph demonstrating the effect of the release of Di-S-TRAIL from sECM-encapsulated mNSCs cultured with U87-mCherry-Fluc cells at increasing ratios of stem cell to tumor cell. After 24 h of culture, fluorescence photomicrographs (top left) were taken, Di-S-TRAIL was visualized by Rluc bioluminescence imaging and tumor cell viability was visualized by Fluc bioluminescence imaging. Scale bars, 100 µm. Data are mean ± s.e.m.